BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 07, 2023 at 03:35 pm EDT
Share
BioLASCO Taiwan Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 73.95 million compared to TWD 56.36 million a year ago. Net income was TWD 13.85 million compared to TWD 11.03 million a year ago. Basic earnings per share from continuing operations was TWD 0.54 compared to TWD 0.43 a year ago. Diluted earnings per share from continuing operations was TWD 0.54 compared to TWD 0.43 a year ago.
For the six months, sales was TWD 123.06 million compared to TWD 106.81 million a year ago. Net income was TWD 20.72 million compared to TWD 17.95 million a year ago. Basic earnings per share from continuing operations was TWD 0.81 compared to TWD 0.7 a year ago. Diluted earnings per share from continuing operations was TWD 0.81 compared to TWD 0.7 a year ago.
BioLASCO Taiwan Co., Ltd. is a Taiwan-based company mainly engaged in the production of Specific Pathogen Free (SPF) laboratory animals and the high-value special-mode experimental animals, as well as the introduction and production of highly-applicable disease-mode animals. The company also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.